{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:32:54Z","timestamp":1790778774795,"version":"4.1.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145633","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T18:49:36Z","timestamp":1451414976000},"page":"e0145633","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro"],"prefix":"10.1371","volume":"10","author":[{"given":"Jennifer D.","family":"K\u00f6nitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sieron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Enenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"issue":"6","key":"ref1","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"P Boross","year":"2012","journal-title":"Am J Cancer Res"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"GJ Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"1 Suppl 2","key":"ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells","volume":"30","author":"P Johnson","year":"2003","journal-title":"Semin Oncol"},{"issue":"Suppl 2","key":"ref4","first-page":"S1","article-title":"Mechanism of action of rituximab","volume":"12","author":"DG Maloney","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"G Cartron","year":"2004","journal-title":"Blood"},{"issue":"56","key":"ref6","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/sj.onc.1207104","article-title":"Monoclonal antibody therapeutics and apoptosis","volume":"22","author":"DL Ludwig","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"PM Cardarelli","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"D Shan","year":"1998","journal-title":"Blood"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","article-title":"CD20-mediated apoptosis: signalling through lipid rafts","volume":"107","author":"JP Deans","year":"2002","journal-title":"Immunology"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.4049\/jimmunol.151.9.4494","article-title":"Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2","volume":"151","author":"JP Deans","year":"1993","journal-title":"J Immunol"},{"issue":"17","key":"ref11","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"HT Chan","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"ref12","first-page":"534","article-title":"Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts\/microdomains of B lymphoma cells","volume":"63","author":"I Semac","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"JK Hofmeister","year":"2000","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"JC Byrd","year":"2002","journal-title":"Blood"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.leu.2402559","article-title":"CD20-induced B cell death can bypass mitochondria and caspase activation","volume":"16","author":"LE van der Kolk","year":"2002","journal-title":"Leukemia"},{"issue":"17","key":"ref16","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"W Alduaij","year":"2011","journal-title":"Blood"},{"issue":"8","key":"ref17","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"A Ivanov","year":"2009","journal-title":"J Clin Invest"},{"issue":"15","key":"ref18","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","article-title":"Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway","volume":"119","author":"J Honeychurch","year":"2012","journal-title":"Blood"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"PJ Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1517\/14712598.7.9.1401","article-title":"Antibody therapeutics: isotype and glycoform selection","volume":"7","author":"R Jefferis","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nbt1207-1369","article-title":"Isotype selection in antibody engineering","volume":"25","author":"JG Salfeld","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.abb.2012.03.021","article-title":"Isotype and glycoform selection for antibody therapeutics","volume":"526","author":"R Jefferis","year":"2012","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2249.2004.02566.x","article-title":"Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass","volume":"138","author":"M Holland","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"1\u20132","key":"ref24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jim.2005.08.009","article-title":"IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides","volume":"306","author":"R Niwa","year":"2005","journal-title":"J Immunol Methods"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1349-7006.2009.01222.x","article-title":"Engineered therapeutic antibodies with improved effector functions","volume":"100","author":"T Kubota","year":"2009","journal-title":"Cancer Sci"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"GL Moore","year":"2010","journal-title":"MAbs"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymeth.2013.06.036","article-title":"Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions","volume":"65","author":"C Kellner","year":"2014","journal-title":"Methods"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11537830-000000000-00000","article-title":"Optimizing therapeutic antibody function: progress with Fc domain engineering","volume":"25","author":"E Kaneko","year":"2011","journal-title":"BioDrugs"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"GA Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.182.5.1545","article-title":"Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl","volume":"182","author":"SJ Martin","year":"1995","journal-title":"J Exp Med"},{"key":"ref31","unstructured":"Durocher Y, Loignon M, inventors; Process, Vectors and Engineered Cell Lines for Enhanced Large-Scale Transfection.US 2011\/0039339 A1. 2009."},{"key":"ref32","article-title":"Molecular Cloning","author":"J Sambrook","year":"2001"},{"key":"ref33","first-page":"31","article-title":"Site-directed mutagenesis using double-stranded plasmid DNA templates","volume":"57","author":"J Braman","year":"1996","journal-title":"Methods Mol Biol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1073\/pnas.63.1.78","article-title":"The covalent structure of an entire gammaG immunoglobulin molecule","volume":"63","author":"GM Edelman","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/pro.5560041120","article-title":"How to measure and predict the molar absorption coefficient of a protein","volume":"4","author":"CN Pace","year":"1995","journal-title":"Protein Sci"},{"issue":"3","key":"ref36","first-page":"406","article-title":"Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia","volume":"24","author":"MJ Robertson","year":"1996","journal-title":"Exp Hematol"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","author":"U von Pawel-Rammingen","year":"2002","journal-title":"EMBO J"},{"issue":"14","key":"ref38","first-page":"3327","article-title":"Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin","volume":"53","author":"WJ Rettig","year":"1993","journal-title":"Cancer Res"},{"issue":"5","key":"ref39","first-page":"1639","article-title":"A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"AM Scott","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0022-1759(94)90110-4","article-title":"CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity","volume":"172","author":"R Lichtenfels","year":"1994","journal-title":"J Immunol Methods"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-B","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody","volume":"30","author":"S Angal","year":"1993","journal-title":"Mol Immunol"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.4049\/jimmunol.164.4.1925","article-title":"Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4","volume":"164","author":"MP Reddy","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0167-5699(95)80094-8","article-title":"The structural requirements for complement activation by IgG: does it hinge on the hinge?","volume":"16","author":"OH Brekke","year":"1995","journal-title":"Immunol Today"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-013-1979-7","article-title":"Accelerated therapeutic progress in diffuse large B cell lymphoma","volume":"93","author":"Q Cai","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620713514682","article-title":"Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers","volume":"5","author":"TM Wildes","year":"2014","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2011.03.004","article-title":"Molecular engineering to improve antibodies' anti-lymphoma activity","volume":"24","author":"M Peipp","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"MT van","year":"2010","journal-title":"Semin Hematol"},{"issue":"16","key":"ref48","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"MJ Glennie","year":"2007","journal-title":"Mol Immunol"},{"issue":"22","key":"ref49","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"E Mossner","year":"2010","journal-title":"Blood"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"JL Teeling","year":"2004","journal-title":"Blood"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"C Klein","year":"2013","journal-title":"MAbs"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"JL Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2567.1996.tb00001.x","article-title":"Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses","volume":"88","author":"N McCloskey","year":"1996","journal-title":"Immunology"},{"issue":"7","key":"ref54","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.4049\/jimmunol.159.7.3372","article-title":"Flexibility of human IgG subclasses","volume":"159","author":"KH Roux","year":"1997","journal-title":"J Immunol"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/j.1460-2075.1988.tb03037.x","article-title":"Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies","volume":"7","author":"JL Dangl","year":"1988","journal-title":"EMBO J"},{"issue":"5947","key":"ref56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/307136a0","article-title":"Correlation between segmental flexibility and effector function of antibodies","volume":"307","author":"VT Oi","year":"1984","journal-title":"Nature"},{"issue":"30","key":"ref57","doi-asserted-by":"crossref","first-page":"20740","DOI":"10.1074\/jbc.M114.572404","article-title":"The Fab conformations in the solution structure of human IgG4 restricts access to its Fc region: implications for functional activity","volume":"289","author":"LE Rayner","year":"2014","journal-title":"J Biol Chem"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"G Niederfellner","year":"2011","journal-title":"Blood"},{"issue":"11","key":"ref59","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.bbapap.2014.07.005","article-title":"Engineering disulfide bonds within an antibody","volume":"1844","author":"Y Hagihara","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pro.352","article-title":"Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding","volume":"19","author":"S Lightle","year":"2010","journal-title":"Protein Sci"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function","volume":"4","author":"H Liu","year":"2012","journal-title":"MAbs"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"AL White","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"ref63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2011-04-346700","article-title":"CD20 antibodies: doing the time warp","volume":"118","author":"MS Cragg","year":"2011","journal-title":"Blood"},{"issue":"6","key":"ref64","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","article-title":"Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density","volume":"11","author":"R Niwa","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2407-9-58","article-title":"Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood","volume":"9","author":"S Iida","year":"2009","journal-title":"BMC Cancer"},{"issue":"11","key":"ref66","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"GA Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:04:55Z","timestamp":1718283895000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145633"}},"subtitle":[],"editor":[{"given":"Sebastian D.","family":"Fugmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145633","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]}}}